Search Results - Robert B. Cameron
- Showing 1 - 8 results of 8
-
1
-
2
-
3
-
4
-
5
What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer? by Robert B. Cameron, Jacobi B. Hines, Valter Torri, Luca Porcu, Jessica Donington, Christine M. Bestvina, Everett Vokes, James M. Dolezal, Alessandra Esposito, Marina C. Garassino
Published in Therapeutic Advances in Medical Oncology (2023-09-01)Get full text
Article -
6
Multi-Institutional Patterns of Use of Tumor-Treating Fields for Patients with Malignant Pleural Mesothelioma by Tugce Kutuk, Joshua M. Walker, Matthew T. Ballo, Robert B. Cameron, Jean Bustamante Alvarez, Sheema Chawla, Eric Luk, Deepti Behl, Alan Dal Pra, Neil Morganstein, Tamer Refaat, Arshin Sheybani, Christian Squillante, Jun Zhang, Rupesh Kotecha
Published in Current Oncology (2023-05-01)Get full text
Article -
7
The majority of patients with resectable incidental lung cancers are ineligible for lung cancer screeningCentral MessagePerspective by Nanruoyi Zhou, MD, John Deng, BS, Claire Faltermeier, MD, PhD, Terrance Peng, MD, MPH, Hanna Mandl, BS, Sha'shonda Revels, MD, MS, Paul Toste, MD, Robert B. Cameron, MD, Jay M. Lee, MD, Jane Yanagawa, MD
Published in JTCVS Open (2023-03-01)Get full text
Article -
8
Pathophysiology and Management of Chest Wall Pain after Surgical and Non-Surgical Local Therapies for Lung Cancer by John Nikitas, MD, Jane Yanagawa, MD, Sandra Sacks, MD, Edward K. Hui, MD, Alan Lee, MD, Jie Deng, MD, PhD, Fereidoun Abtin, MD, Robert Suh, MD, Jay M. Lee, MD, Paul Toste, MD, Bryan M. Burt, MD, Sha’Shonda L. Revels, MD, Robert B. Cameron, MD, Drew Moghanaki, MD, MPH
Published in JTO Clinical and Research Reports (2024-07-01)Get full text
Article
